protamine sulphate

CLINICAL USE

Counteract anticoagulant effect of heparin

DOSE IN NORMAL RENAL FUNCTION

Depends on time since stopping IV/subcutaneous heparin and dose of heparin given

PHARMACOKINETICS

Molecular weight :Approx 4500

%Protein binding :1

%Excreted unchanged in urine : No data

Volume of distribution (L/kg) :12.3 litres

half-life – normal/ESRD (hrs) :7.4 minutes/–

DOSE IN RENAL IMPAIRMENT

GFR (mL/MIN)

20 to 50 : Dose as in normal renal function

10 to 20 : Dose as in normal renal function

<10 : Dose as in normal renal function

DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

CAPD :Unknown dialysability. Dose as in normal renal function

HD :Unknown dialysability. Dose as in normal renal function

HDF/high flux :Unknown dialysability. Dose as in normal renal function

CAV/VVHD :Unknown dialysability. Dose as in normal renal function

IMPORTANT DRUG INTERACTIONS

Potentially hazardous interactions with other drugs

None known

ADMINISTRATION

Reconstition

–

Route

–

Rate of Administration

5 mg/minute

Comments

–

OTHER INFORMATION

Counteracting the anticoagulant effect of heparin during extra-corporeal treatments requires approximately 1.5 mg protamine per 100 IU heparinMost clinicians recommend a dose of 1–1.5 mg protamine sulphate for each 100 units heparin given depending on the length of time since heparin administrationMay be used topically to stop bleeding fistulae

See how to identify renal failure stages according to GFR calculation

See how to diagnose irreversible renal disease

Home